Systemic sclerosis & Raynaud's
Association of the Apollo Wearable With Fatigue, Raynaud Phenomenon, and Quality of Life in Patients With Systemic Sclerosis: A Pilot Study
Authors' conclusion
Use of the Apollo wearable for 4 weeks was associated with improvement in fatigue and RP symptoms in patients with SSc, with improved QOL measures, lower depression scores, and improved disability measures.
Study context
- Population
- Adults with systemic sclerosis (SSc), moderate fatigue and Raynaud phenomenon (RP)
- Participants
- 25 adults
- Comparison
- Apollo wearable device worn daily for a minimum of 15 minutes for 4 weeks (before vs after)
- Outcome
- Change on PROMIS Fatigue 13a
- Follow-up
- 4 weeks
Methodological detailssingle-group, 4-week intervention
- Single-group
- 4-week intervention
Main finding
As reported in the abstract
PROMIS Fatigue
- Less fatigue reported (P < 0.001)
Further findings
Average daily number of RP attacks · 4 weeks
- Declined
- P = 0.007
Raynaud Condition Score · 4 weeks
- Declined
- P = 0.007
Average device usage
- Average device usage (hours/day), far exceeded the requested time
- 2.87
PROMIS-29 subscores (quality of life (QOL))
- Improvement in physical function
- P = 0.01
- Improvement in depression
- P = 0.03
- Improvement in fatigue
- P = 0.01
- Improvement in sleep disturbance
- P = 0.002
- Improvement in ability to participate in social roles and activities
- P < 0.001
Depression measure
- Significant improvement
- P = 0.004
Disability measure
- Significant improvement
- P < 0.05
Safety
- No adverse events occurred
Original publication
Association of the Apollo Wearable With Fatigue, Raynaud Phenomenon, and Quality of Life in Patients With Systemic Sclerosis: A Pilot Study. J Rheumatol. Published 1 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →